Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Corcept Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was $-127.0 Mil. Corcept Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $642.9 Mil. Therefore, Corcept Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -19.76%.
The historical rank and industry rank for Corcept Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
CORT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.31 Med: 24.42 Max: 111.15
Current: 7.31
During the past 13 years, Corcept Therapeutics's highest Return-on-Tangible-Equity was 111.15%. The lowest was 7.31%. And the median was 24.42%.
CORT's Return-on-Tangible-Equity is ranked better than 83.85% of 1201
companies
in the Biotechnology industry
Industry Median: -42.4
vs CORT: 7.31
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Corcept Therapeutics Return-on-Tangible-Equity Related Terms
Corcept Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CORT vs PRAX, IBRX, NUVL: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Corcept Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -19.76% mean?
Corcept Therapeutics (CORT) has a Return-on-Tangible-Equity of -19.76% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Corcept Therapeutics and its competitors. Over the past decade, Corcept Therapeutics' Return-on-Tangible-Equity has ranged from 7.31 to 111.15. According to the industry distribution chart, Corcept Therapeutics ranks #194 out of 1201 companies in the Biotechnology industry, placing it in the top 16.2%.
Is Corcept Therapeutics' Return-on-Tangible-Equity too high?
Corcept Therapeutics' current Return-on-Tangible-Equity is -19.76%. Over the past 10 years, this metric has ranged from a low of 7.31 to a high of 111.15. Based on the distribution chart, Corcept Therapeutics ranks #194 out of 1201 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Return-on-Tangible-Equity compare to PRAX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #194 out of 1201 companies for Return-on-Tangible-Equity. This places Corcept Therapeutics in the top 16% of its industry — outperforming the majority of peers. Historically, Corcept Therapeutics' own Return-on-Tangible-Equity has ranged from 7.31 to 111.15 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Return-on-Tangible-Equity is -19.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $61.67, compared to a current price of $87.89 — trading 42.5% above its estimated fair value. The current Return-on-Tangible-Equity is -19.76%. Corcept Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current Return-on-Tangible-Equity is -19.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (CORT) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of $87.89 is trading 42.5% above its estimated GF Value™ of $61.67.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for CORT:
Return-on-Tangible-Equity: -19.76%
GF Value™: $61.67 vs. price of $87.89 (42.5% above fair value)
No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score
Get the complete analysis for CORT
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CORT has been successfully added to your 
